1. Recommendation of NLA Expert Panel on Treatment With PCSK9 Inhibitors
Secondary Prevention FH
Stable CVD + CVD RF
ProgressiveCVD
Age 40-79
FH Phenotype
LDL-C ≥190 mg/dl (pre treatment)
LDL-C ≥130 mg/dl (max. tolerated treatment)
Uncontrolled RF/markers - optional
Genetic confirmation - optional
Max statin + Ezetimibe
On treatment LDL ≥70 mg/dl
On treatment Non-HDL ≥100 mg/dl
Age 18-39
FH Phenotype
LDL-C ≥190 mg/dl (pre treatment)
LDL-C ≥130 mg/dl (max. tolerated treatment)
Uncontrolled RF/markers or
Genetic confirmation
Very-High Risk +
Statin Intolerant
Statin intolerance based on NLA expert panel
On treatment LDL ≥70 mg/dl
Require substantial additional atherogenic cholesterol lowering
Homozygous FH
Unknown genotype or LDL-receptor defective
LDL-C ≥70 mg/dl (max tolerated treatment )